New findings are a window into the late stages of 'Lou Gehrig's' disease

February 4, 2004 - BETHESDA, MD -- Amyotrophic lateral sclerosis (ALS) may be better known to some as "Lou Gehrig's disease," a reference to the great New York Yankees hitter and teammate of Babe Ruth who was struck down by the disease. Some 30,000 Americans now suffer from this disabling, almost invariably fatal, disease that is caused by the degeneration of the body's motor neurons, muscle atrophy and weakness.

No one knows what causes the process of terminal neurodegernation to begin. However, using a two-step process to analyze 6,800 genes, scientists have now found an ALS-specific "signature" in spinal cord gray matter taken from ALS patients. The researchers were also able to distinguish familial ALS (FALS) from sporadic ALS (SALS). They believe their approach can reveal some of the distinct changes that underlie the terminal stages in the disease.

A New Study

The new study is entitled "The Molecular Signature of Late-Stage Human ALS Revealed By Expression Profiling of Post-Mortem Spinal Cord Gray Matter." The authors are Fernando Dangond and Sandra Camelo, Laboratory of Transcriptional and Immune Regulation, Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Daehee Hwang, Gregory Stephanopoulos and George Stephanopoulos, of the Bioinformatics and Metabolic Engineering Laboratory, Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA; Piera Pasinelli and Robert H. Brown, Jr., of the Day Neuromuscular Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Matthew P. Frosch, from the C.S. Kubik, Laboratory of Neuropathology, Department of Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Steven R. Gullans of the Laboratory of Functional Genomics, Department of Neurology, Harvard Medical School, Boston, MA. Their findings are published in the January 2004 edition of Physiol

Contact: Donna Krupa
American Physiological Society

Page: 1 2 3

Related biology news :

1. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
2. Virginia Tech researchers to release findings on Smith River Project
3. New HIV findings
4. Stanford researchers findings may shed light on common, deadly birth defect
5. Briggs takes to the molecular level Darwins findings on plants sensing the direction of light
6. Latest findings on PCBs to be subject of June workshop at Illinois
7. Chlamydia in men now also linked to infertility new findings
8. New MS research shows remarkable findings
9. Scientists findings may lead to better understanding of how that sleep develops, matures
10. New findings bring mixed blessings to those looking to combat jet lag
11. New findings can help parents looking to combat number of kids sick days

Post Your Comments:

(Date:4/23/2020)... ... April 23, 2020 , ... ... recruitment plans. MDG provides critical infrastructure products for the animal feed, human consumption, ... plans for expansion. Further, as supply channels from overseas competitors have become weakened ...
(Date:4/22/2020)... ... April 21, 2020 , ... Captis ... venture capital firm that provides patent development support for early stage startups. The ... illnesses such as ovarian cancer and precancerous pancreatic lesions with simple, accurate and ...
(Date:4/22/2020)... ... , ... Worcester Polytechnic Institute (WPI) is expanding an existing science and engineering ... expected spike of COVID-19 cases. As part of its longtime Math and Science for ... other materials to be sent to six countries to facilitate the manufacturing of masks, ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... ... 2020 , ... Children with defective heart valves often have ... adults. The reason: there are no heart valve prosthetics designed to grow with ... Defense has awarded Draper, Boston Children’s Hospital and Seattle Children’s Research Institute a ...
(Date:5/15/2020)... ... 15, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel ... Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he ... Brian Miller and Sentien’s management team. , Mr. Ganz has more than ...
(Date:5/14/2020)... ... May 12, 2020 , ... ... translational research, is bringing together thousands of industry leaders, clinicians, research scientists, medical ... two plenary speakers, Carl June, MD, Director of the Center for Cellular Immunotherapies ...
(Date:5/14/2020)... ... May 13, 2020 , ... ... or phenotypic readouts, providing little or no information on the drug’s mechanism of ... comprehensive characterization of compounds by measuring the activity of molecular pathways. This information ...
Breaking Biology Technology:
Cached News: